In the Diabetes & Dementia (D2) prospective cohort study of 123 adults over 50 with type 2 diabetes (T2DM), left ventricular hypertrophy (LVH) — detected by echocardiography — was causally associated with 6.3 cm³ less total brain volume loss over two years (95% CI: 0.1–12.5 cm³, P=.048) compared to those without LVH, using inverse probability of treatment weighting to control for confounding. Notably, LVH showed no significant effect on cognitive decline. Baseline cognitive impairment, hypertension, and lower educational attainment were the strongest predictors of cognitive deterioration.
This counterintuitive finding challenges the assumed linear pathway from cardiac pathology to brain damage in T2DM. The authors suggest that guideline-directed LVH therapies — particularly beta-blockers — may confer neuroprotective benefits alongside cardiac ones, possibly through blood pressure stabilization or reduced cerebral pressure variability. However, this preprint has not yet been peer-reviewed, and the causal inference analysis rested on only 93 participants after positivity exclusions, severely limiting statistical power. The 17.4% attrition rate and single-city Australian recruitment further constrain generalizability. The apparent brain-protective signal from LVH may reflect survivorship bias, medication effects, or unmeasured compensatory hemodynamics rather than a true cardio-neuroprotective mechanism. Replication in larger, more diverse cohorts is essential before any clinical implications can be drawn. This is an intriguing, potentially paradigm-complicating result — but one demanding considerable caution.
